MedTrace Logo

Hallux Mobilization in Patients With Parkinson's Disease

NCT02098642 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2014-03-28

No results posted yet for this study

Summary

Parkinson's disease is a degenerative disorder of the central nervous system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain; the cause of this cell death is unknown. Early in the course of the disease, the most obvious symptoms are movement-related; these include shaking, rigidity, slowness of movement and difficulty with walking and gait. A multidisciplinary intensive rehabilitation treatment (MIRT) is able to improve different parameters in PD that are poorly responsive to dopaminergic therapy. In this study, we aim to understand whether the passive mobilization of the metatarsophalangeal joint of the hallux determines an increase in the joint range in this district, allowing to improve, at least, the gait.

Conditions

  • Parkinson Disease

Interventions

OTHER

MIRT

A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.

OTHER

Mobilization of the metatarsophalangeal joint of the hallux

MIRT and mobilization of the metatarsophalangeal joint of the hallux

Sponsors & Collaborators

  • Ospedale Generale Di Zona Moriggia-Pelascini

    lead OTHER

Principal Investigators

  • Giuseppe Frazzitta, MD · Ospedale Generale Di Zona Moriggia-Pelascini

Eligibility

Min Age
49 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-11-30
Completion
2014-02-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02098642 on ClinicalTrials.gov